Italia markets open in 7 hours 45 minutes

EDIT Jan 2026 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,68000,0000 (0,00%)
In data: 11:19AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,6800
Aperto0,6500
Denaro0,0000
Domanda0,9000
Prezzo d'esercizio17,50
Scadenza2026-01-16
Min-Max giorno0,6500 - 0,6800
Contratto - Min-MaxN/D
Volume30
Open Interest176
  • GlobeNewswire

    Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

    CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). “Sickle cell disease is a devastating disease that leads to anemia, pain crises, organ failure, and early death. Receiving RMAT

  • GlobeNewswire

    Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

    CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordan

  • GlobeNewswire

    Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

    Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support a